|
Palo Alto, CA, January 4, 2005 — Telik, Inc. (Nasdaq: TELK) announced that company management will present an update at the 23 rd Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 10, 2005 at 3:00 p.m. Pacific time (6:00 p.m. Eastern time). A live webcast of the presentation will be accessible at Telik’s website, www.telik.com. An archive of the webcast will be available on the Telik website through January 17, 2005.
Telik, Inc. of Palo Alto , CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate that is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
